MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Phase 3 Recruiting
492 enrolled
Pre-malignant States to Hematologic Malignancies in Firefighters
Recruiting
300 enrolled
Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma
Phase 2 Recruiting
30 enrolled
Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants
Recruiting
1,000 enrolled
Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma
Phase 1 Recruiting
15 enrolled
Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma
Phase 1/2 Recruiting
44 enrolled
REALIZE
Phase 1 Recruiting
60 enrolled
Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
Phase NA Recruiting
400 enrolled
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Phase 1 Recruiting
125 enrolled
Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy
Phase NA Recruiting
40 enrolled
A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma
Phase 1 Recruiting
30 enrolled
EASE
Phase 2 Recruiting
100 enrolled
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
Phase 1/2 Recruiting
49 enrolled
Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma
Phase 2 Recruiting
39 enrolled
LIBERATE
Recruiting
2,500 enrolled
Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders
Phase 1/2 Recruiting
30 enrolled
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Recruiting
15,000 enrolled
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)
Phase 2/3 Recruiting
900 enrolled
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig)
Phase 2/3 Recruiting
900 enrolled
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig)
Phase 2/3 Recruiting
900 enrolled
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig)
Phase 2/3 Recruiting
900 enrolled
HEME Home Transfusion Program
Phase NA Recruiting
700 enrolled
Impact of Recombinant Human Interleukin-7 (CYT107) on Tumor Clearance and Immune Reconstitution in Multiple Myeloma Patients After Autologous Hematopoietic Cell Transplant
Phase 1 Recruiting
30 enrolled
A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma
Phase 2 Recruiting
20 enrolled
MYRACLE
Recruiting
1,400 enrolled
A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
Phase NA Recruiting
60 enrolled
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Recruiting
Registry of Older Patients With Cancer
Recruiting
3,000 enrolled
BAH2573
Phase 1/2 Recruiting
60 enrolled
High Dose Ascorbic Acid (HDAA) in Patients With Plasma Cell Disorders
Phase 1 Recruiting
18 enrolled
SBRT Plus Lenalidomide for Solitary Plasmacytoma: Phase II Trial
Phase 2 Recruiting
41 enrolled
BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
Phase 1/2 Recruiting
80 enrolled
a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
Phase 1/2 Recruiting
80 enrolled
Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
Phase 2 Recruiting
15 enrolled
Longitudinal Data Registry of Plasma Cell Dyscrasia
Recruiting
2,000 enrolled
Survivorship
Recruiting
45 enrolled
BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma
Phase 1/2 Recruiting
10 enrolled
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
Phase 1 Recruiting
81 enrolled
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
Phase 1/2 Recruiting
78 enrolled
PRONTO
Phase 2 Recruiting
100 enrolled
Myelofludate
Phase 1 Recruiting
35 enrolled
Chemotherapy Combined With Radiotherapy Versus Radiotherapy Alone for Solitary Plasmacytoma
Phase 2 Recruiting
220 enrolled
RATIONALISE
Phase 2/3 Recruiting
300 enrolled
Bergamo Lymphoid Cancer Registry
Recruiting
6,000 enrolled
ENROL
Recruiting
37,090 enrolled
CAR-T
Phase 1/2 Recruiting
20 enrolled
A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma
Phase 1/2 Recruiting
36 enrolled
TMF-Allo
Phase 2 Recruiting
150 enrolled
Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies
Phase 1 Recruiting
10 enrolled